PHARMACEUTICAL

SECTOR
NAME :- CHINMAY POL
DIV ROLLNO:- CF-8
SUBJECT :- INDUSTRY ANALYSIS AND DESK RESEARCH
 CONTENTS

 INTRODUCTION
 MARKET SIZE
 EXPORTS
 INVESTMENTS AND DEVELOPMENTS
 TOP PLAYERS
 INTRODUCTION

 India is the largest provider of generic drugs globally. Indian pharmaceutical

sector supplies over 50% of global demand for various vaccines, 40% of generic
demand in the US and 25% of all medicine in the UK. Globally, India ranks 3rd in
terms of pharmaceutical production by volume and 14th by value. The domestic
pharmaceutical industry includes a network of 3,000 drug companies and ~10,500
manufacturing units.

 India enjoys an important position in the global pharmaceuticals sector. The

country also has a large pool of scientists and engineers with a potential to steer
the industry ahead to greater heights. Presently, over 80% of the antiretroviral
drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome)
are supplied by Indian pharmaceutical firms.
 MARKET SIZE

 According to the Indian Economic Survey 2021, the domestic market is expected to
grow 3x in the next decade. India’s domestic pharmaceutical market is estimated at
US$ 42 billion in 2021 and likely to reach US$ 65 billion by 2024 and further expand
to reach ~US$ 120-130 billion by 2030.

 India's biotechnology industry comprising biopharmaceuticals, bio-services, bio-

agriculture, bio-industry, and bioinformatics. The Indian biotechnology industry was
valued at US$ 64 billion in 2019 and is expected to reach US$ 150 billion by 2025.

 India’s medical devices market stood at US$ 10.36 billion in FY20. The market is
expected to increase at a CAGR of 37% from 2020 to 2025 to reach US$ 50 billion.
 EXPORTS

 India’s drugs and pharmaceuticals exports stood at US$ 24.44 billion in FY21.
India is the 12th largest exporter of medical goods in the world. The country’s
pharmaceutical sector contributes 6.6% to the total merchandise exports. As of
May 2021, India supplied a total of 586.4 lakh COVID-19 vaccines, comprising
grants (81.3 lakh), commercial exports (339.7 lakh) and exports under the
COVAX platform (165.5 lakh), to 71 countries. Indian drugs are exported to more
than 200 countries in the world, with US being the key market. Generic drugs
account for 20% of the global export in terms of volume, making the country the
largest provider of generic medicines globally.
Investments and Recent Developments

 In June 2021, Sun Pharmaceuticals acquired the patent license for Dapagliflozin from
AstraZeneca. The company will be distributing and promoting the drug under the brand name
‘Oxra’.
 In June 2021, Lupin Ltd. announced its intention to enter the digital healthcare space in India. It
incorporated Lupin Digital Health Ltd., a wholly owned subsidiary, to provide a digital
therapeutics platform for medical practitioners and patients in the country.
 In May 2021, Cipla launched a real-time COVID-19 detection kit ‘ViraGen’ that is based on
multiplex polymerase chain reaction (PCR) technology.
 In May 2021, the Government of India invited R&D proposals on critical components and
innovations in oxygen concentrators by June 15, 2021.
 In May 2021, Indian Immunologicals Ltd. (IIL) and Bharat Immunologicals and Biologicals
Corporation (BIBCOL) inked technology transfer pacts with Bharat Biotech to develop the
vaccine locally to boost India's vaccination drive. The two PSUs plan to start production of
vaccines by September 2021.
TOP
PLAYERS SUN PHARMA
 Sun Pharmaceuticals is the largest pharmaceutical company from
India and the fifth largest specialty generic company in the world.
It has capabilities across dosage forms like injectables, sprays,
ointments, creams, liquids, tablets, and capsules. Its businesses
include producing generics, branded generics, speciality, over the
counter (OTC) products, anti-retrovirals (ARVs), active
pharmaceutical ingredients (APIs) and intermediates in the full
range of dosage forms. It also produces specialty APIs. In FY19,
US formulations contributed the most to company’s sales with
37%, followed by India branded formulations at 26%.

 Company Website: www.sunpharma.com

 CIPLA

 Cipla is a leading pharmaceutical from India with

presence across the world. It was established in 1935 as
Chemical Industrial & Pharmaceutical Laboratories Ltd
and changed to its current name in 1984. The company
has a vast portfolio with more than 1,500 products in the
market. The company’s business is divided into three
strategic units - APIs, respiratory and Cipla Global
Access. Its largest market is India, followed by Africa
and North America. Company’s total revenue reached
Rs. 17,132 crore (US$ 2.43 billion) in FY20.

 Company Website: www.cipla.com

 LUPIN
 Lupin Ltd. is a leading pharmaceutical company
from India and is amongst the top 10 generic
companies in the world. It started its business in
1968 and over the years has become one of the
largest pharmaceutical companies in India and the
world. Its businesses include formulations, Active
Pharmaceutical Ingredients (API), drug delivery
systems and biotechnology. In FY20, Lupin’s total
sales stood at Rs. 15,142.8 crore (US$ 1.72 billion).

 Company Website: http://www.lupin.com

THANK YOU